Egypt. J. Chem. Vol. 67, SI: M. R. Mahran, pp. **1387 - 1398** (2024)

Egyptian Journal of Chemistry

http://ejchem.journals.ekb.eg/

Biochemical Pathophysiology of Hypertension: Nursing Interventions in Blood Pressure Regulation and Treatment

Khadij Barri Ahmad Qaissi[1], Maram Abdullah Almutiri[2], Mariam Kassb Alrowili[3], Tasneem Saeed Almahroos[4], Amnah Farhan Albaker[4], Salha Jubran Yahya Aqeeli[4], Nadiah Munahi Al-Mutairi[4], Ashwaq Ali Almohsen[5], Tala Saeed Almutiari[4], Bashaeraa[6] Attalah Bakyt Alanazy[7], Awatif Muteb Rajah Almuteri[5], Mariam Mohammed Almutiri[8], Abdullah Mashlah Aldosari[9], Fatimah Hassan Al Abbas[10], Afaf Ahmad Kriri[11]

1 Primary Health Care Center, Ministry of Health, Saudi Arabia
2 Qassim Gathering, Ministry of Health, Saudi Arabia
3 Hafr Al-Batin Health Cluster, Ministry of Health, Saudi Arabia
4 Second Health Cluster, Ministry of Health, Saudi Arabia
5 Riyadh Health Cluster II, Ministry of Health, Saudi Arabia
6 King Khalid Hospital, Ministry of Health, Saudi Arabia
7 Cluster2_Riyadh, Riyadh - Airport Primary Health Care Center, Ministry of Health, Saudi Arabia
8 Wadi Al Dawasir Hospital, Ministry of Health, Saudi Arabia
9 First Health Cluster Al-Adamah Health Care Center, Ministry of Health, Saudi Arabia
10 The first health cluster - King Khalid Al-Kharj Hospital, Ministry of Health, Saudi Arabia
11 Al-Kattar District Health Center in Al-Kharj, Ministry of Health, Saudi Arabia.

Abstract

Background: Hypertension is a major public health issue worldwide, with high prevalence rates but low levels of awareness, treatment, and control. Despite its impact on cardiovascular health and its association with numerous risk factors, the management of hypertension remains suboptimal, particularly in low-resource settings. Emerging risk factors such as sugar intake, air and noise pollution, and low birth weight add complexity to the condition's pathophysiology. Effective hypertension management requires accurate diagnosis, improved treatment adherence, and tailored interventions across multiple healthcare sectors.

Aim: This article aims to examine the biochemical pathophysiology of hypertension and explore the role of nursing interventions in blood pressure regulation and treatment. It will also highlight the emerging risk factors, current challenges in hypertension management, and the importance of biomarkers in improving diagnosis and treatment.

Methods: A review of current literature on hypertension management was conducted, focusing on risk factors, challenges in diagnosis and control, and emerging strategies to improve treatment adherence. Relevant clinical guidelines and research on biomarkers were also analyzed to understand their role in hypertension care.

Results: The article identifies several emerging hypertension risk factors such as sugar intake, air pollution, and noise, which complicate treatment strategies. Challenges in hypertension management include inadequate health services, difficulty in diagnosing hypertension, and poor treatment adherence. Biomarkers, including genetic, molecular, and functional biomarkers, hold significant promise for early diagnosis, risk stratification, and personalized treatment strategies. The article also emphasizes the roles of patients, physicians, health authorities, nurses, and pharmacists in improving hypertension management.

Conclusion: The future of hypertension management lies in enhancing awareness, improving diagnostic accuracy, and integrating new biomarkers into clinical practice. National programs, targeted interventions, and financial coverage expansion are crucial to improving blood pressure control, particularly in resource-limited settings. Nurses, alongside physicians and other healthcare providers, have an essential role in patient education and adherence strategies. Effective integration of biomarkers into routine care could revolutionize hypertension management and lead to better long-term outcomes.

Keywords: Hypertension, biomarkers, blood pressure control, risk factors, nursing interventions, treatment adherence, genetic biomarkers, emerging risk factors, healthcare challenges.

1. Introduction

Due to advancements in knowledge, treatment, and management, the prevalence of hypertension is decreasing in Western developed nations, but it is either staying the same or rising in emerging nations. Systolic blood pressure (SBP) rose in poor countries and fell in high-income countries between 1980 and 2008 [1]. Given that age is a major risk factor for hypertension, the aging population is one of the causes contributing to the increased prevalence. Urbanization, which results in food and lifestyle changes [2, 3], the rising rates of obesity, diabetes, and metabolic syndrome [4], and physical inactivity are further contributing factors. One of the main causes of the rising prevalence of hypertension is urbanization; in emerging nations, urban regions tend

*Corresponding author e-mail: kbqaissi@moh.gov.sa.; (Khadij Barri Ahmad Qaissi).
Receive Date: 13 November 2024, Revise Date: 25 November 2024, Accept Date: 01 December 2024
DOI: 10.21608/ejchem.2024.336261.10800

to have greater levels of hypertension than rural ones. Furthermore, there has been a discernible movement in emerging nations toward Western dietary patterns, marked by a decline in fiber intake and an increase in animal products, refined grains, fats, salts, and sweets [5, 6]. In certain developing nations, air and noise pollution are additional risk factors for hypertension that are connected to industrialization and overpopulation [7, 8, 9, 10, 11]. In many underdeveloped nations, low birth weight is prevalent and linked to a higher chance of having hypertension in later life [12]. Furthermore, enhancing the prevention and management of hypertension is severely hampered by a lack of funding, a weak healthcare system, and a general lack of medical literacy.

High Prevalence and Low Awareness, Treatment, and Control Rates:

The prevalence of hypertension was 28.5% in high-income countries and 31.5% in low- and middle-income countries in 2010, according to Mills et al. [13], who conducted a comprehensive review of population-based studies comprising 968,419 individuals spanning 135 populations in 90 countries. The prevalence of hypertension rose 7.7% in low- and middle-income nations between 2000 and 2010, while it fell 2.6% in high-income countries. Compared to high-income countries, low- and middle-income countries had much lower rates of hypertension awareness, treatment, and control. While progress in low- and middle-income nations has been slower, high-income countries have witnessed significant gains in hypertension awareness, treatment, and management over the past few decades [13]. The prevalence, awareness, treatment, and control of hypertension in rural and urban settings across high-, middle-, and low-income countries were investigated in the Prospective Urban Rural Epidemiology (PURE) study [14], which found that the treatment rate was 31.7% in low-income countries and 46.7% in high-income countries. Less than 10% of people with hypertension have access to adequate therapy, according to recent World Health Organization (WHO) data for South Africa and Ghana [15]. Generally speaking, treatment rates in Western nations fall between 50% to 80% [16], while they are significantly lower in poorer nations like China (22%) [18] and Indonesia (25% [17]. Additionally, control rates differ greatly, ranging from 5.3% in China to 10.1% in India [19].

Hypertension Risk Factors:

The main behavioral variables contributing to the rising prevalence of hypertension worldwide include obesity, physical inactivity, and poor diet (including high intakes of alcohol and salt, as well as low intakes of fruits and vegetables). Due to nutritional changes, social stress, and a lack of physical activity, urbanization is growing quickly globally—is linked to greater incidence of hypertension. According to WHO statistics from 2016, 49% of adults in Iraq and 32% of adults in Egypt were not physically active enough. In nations like Mexico, Egypt, and South Africa, women are disproportionately overweight or obese [20]. Siervo et al. [21] found a direct correlation between the prevalence of obesity and hypertension and excessive consumption of meat, animal fats, and milk. Furthermore, developing nations are increasingly consuming meals heavy in salt [22]. A worrying trend is the rise in childhood hypertension prevalence, which currently affects 5–10% of children in poor nations and 1-2% of children in industrialized nations [23]. An analysis of 2,166 school-age children in western Turkey revealed that 18% were obese and 15.1% had hypertension [24].

Emerging Hypertension Risk Factors

Sugar and Hypertension:

Although it is still preliminary, recent research indicates that additional sugars, especially those in soft drinks, may have a direct impact on blood pressure without being related to obesity [25]. According to a study of 12 research with 407,707 individuals, drinking sugar-sweetened drinks (SSBs) raises blood pressure [26]. Brown et al. [27] discovered links between high blood pressure and added sugars, diet sodas, and SSBs. Sugars that contain fructose are believed to be important contributors to the development of metabolic syndrome, obesity, and hypertension [28]. Global sugar consumption has been gradually increasing over the last 50 years, and emerging economies—particularly those in East Asia, Latin America, and India—have been a major contributor to this trend [29]. The American Heart Association has established a stricter upper limit of 6% [31], whereas the World Health Organization (WHO) advises that added sugar consumption should not exceed 10% of total energy intake [30].

Air Pollution:

In developing countries, indoor and outdoor air pollution is a serious health concern. In these areas, uncontrolled city growth and rapid urbanization create environmental risks including industrialization and overcrowding, which both increase air pollution. It is well recognized that prolonged exposure to household and ambient air pollution can negatively impact the cardiovascular system, leading to hypertension [7]. East Asian nations experience exceptionally high levels of air pollution as a result of their fast industrialization and dense smog. Long-term exposure to air pollution has been linked to elevated blood pressure and hypertension in Chinese populations, according to Dong et al. [9], albeit this association was only statistically significant in men. Living in an oil-polluted environment was nearly five times more likely to result in hypertension, according to a study conducted in Nigeria's Niger Delta region [8]. Health consequences are further complicated by the

association between low birth weight and indoor air pollution exposure during pregnancy [7].

Noise Pollution:

In developing nations, industrialization, urbanization, and overcrowding all lead to increased noise exposure, which is linked to hypertension on its own. DeSouza et al. [11] found a link between hypertension and occupational noise exposure in Rio de Janeiro, Brazil, among petrochemical workers. Similarly, among Chinese steel workers, cumulative noise exposure was associated with hypertension [10]. It has been demonstrated that prolonged exposure to noise levels higher than 85 dB increases the risk of hypertension [11].

Low Birth Weight:

Compared to industrialized countries, low birth weight (LBW) is more common in developing countries, especially in South Asia, where the proportion of LBW infants worldwide is highest [32]. LBW in neonates is prevalent in Yemen (45%), Sudan (32.3%), and Pakistan (32%), according to WHO data [33]. Particularly in South Asia, there is a well-established link between low birth weight and the onset of adult hypertension [12, 34].

Inadequate Health Services:

More than half of the world's population still does not have access to basic health services, despite improvements in health systems. Lack of health insurance, conflicting investment goals, and a lack of funding for healthcare are some of the issues that many developing nations confront. For example, Eritrea spends only US $12 per capita on healthcare, compared to US $8,362 per capita in the United States [35]. According to recent WHO statistics, the high out-of-pocket expenditure in countries like Afghanistan (63%), Sudan (75.5%), Pakistan (56.3%), and Egypt (55.7%) indicates that patients in poorer countries bear the majority of healthcare costs [33]. Furthermore, there is a major scarcity of healthcare workers in developing nations, with Egypt (8.4), Yemen (3.0), Afghanistan (2.7), and Djibouti (2.1 physicians per 10,000 population) all experiencing severe shortages [33].

Major Challenges in the Management of Hypertension

Accurate Diagnosis of Hypertension:

The process of getting precise and repeatable blood pressure readings is fraught with serious and well-established difficulties. The lack of a straightforward, accurate, and dependable blood pressure measurement tool is a major factor in the rising incidence of hypertension in African nations [36]. Instead of depending just on clinic-based readings, the British Hypertension Society's guidelines, as presented by NICE [37], suggest that 24-hour ambulatory blood pressure monitoring (ABPM) be used as the gold standard for diagnosing hypertension. Similarly, if clinic readings are ≥140/90 mmHg or if hypertension is suspected, the new Australian Guidelines [38••] recommend providing ambulatory or home blood pressure monitoring to confirm hypertension. The preferred approach for diagnosing hypertension is automated office blood pressure measurement, according to the 2017 Canadian Guidelines [39]. Accordingly, the World Health Organization (WHO) and the World Hypertension League (WHL) have recommended the use of automated blood pressure monitors as a way to increase the precision of blood pressure readings, especially in environments with limited resources [40, 41].

Improving Blood Pressure Control:

Uncontrolled hypertension is still quite common and is still on the rise, especially in low- and middle-income nations where control rates are startlingly low—in certain places, like Africa, control rates are as low as 2% [42]. In Nepal, a community-based cross-sectional study [43] investigated the obstacles to managing and treating hypertension and found a number of factors that lead to poor drug adherence. The asymptomatic nature of hypertension, the lengthy course of treatment, complicated medication regimens, the requirement for multiple tablets, frequent dosing schedules, the high cost of pharmaceuticals, the lack of motivation, the perception of no immediate benefits, adverse drug reactions, and worries about possible harm are some of these. Furthermore, research from Brazil, Thailand, the US, the UK, and the Netherlands [44] found that some patients purposefully cut back on or avoid taking their medications. Because they deny their condition, patients in Malaysia frequently postpone or avoid follow-up appointments [45]. Additionally, Attaei et al. [46] examined the accessibility, affordability, and cost of blood pressure-lowering drugs in 20 PURE project participating nations. According to their research, a sizable section of the populace in low- and middle-income nations do not have access to a range of blood pressure-lowering drugs, and when they do, they are frequently too expensive.

Measures to Improve Hypertension Control:

Collaboration between patients, doctors, health authorities, and medical societies is necessary to improve blood pressure regulation. A number of tactics can be used to improve hypertension management. In addition to increasing treatment adherence and making lifestyle modifications, patients can help by taking their blood pressure at home and practicing self-monitoring. By educating patients, encouraging them, and giving generic drugs that are less expensive and require fewer doses, doctors can help manage efforts. Other crucial procedures include recommending more frequent clinic visits and prescribing single-pill combinations for once-daily dosage. By offering health insurance, encouraging the use of generic medications, enacting salt reduction regulations aimed at the food industry and dining establishments, supporting collaborative education initiatives with medical societies, providing opportunistic blood pressure checks, setting up

hypertension clinics, and integrating nurses and pharmacists in patient care, health authorities can play a crucial role. Establishing specialized hypertension clinics, educating doctors, nurses, and pharmacists, creating and sharing national hypertension guidelines, and raising patient and public awareness via telemedicine, social media, and the internet are all ways that medical societies can help with these initiatives. Furthermore, universal screening might be made easier by placing blood pressure monitoring devices in public areas like shopping centers and train stations.

Role of Patients:

When used in conjunction with patient education, self-blood pressure monitoring and home blood pressure measurement have been shown to improve hypertension control. Home monitoring dramatically lowers mean systolic and diastolic blood pressure, improving hypertension treatment, according to meta-analyses of randomized studies [47, 48]. Home blood pressure monitoring is recommended by recent guidelines as a crucial part of managing hypertension. When compared to traditional care, home blood pressure control has been shown to dramatically lower blood pressure in high-income nations [49]. People who used automated interactive voice response messages in conjunction with blood pressure monitoring equipment had lower systolic blood pressure (SBP) than those in control groups, according to a clinical experiment done in Mexico and Honduras [50]. Additionally, compared to usual treatment, self-monitoring combined with self-titration of antihypertensive drugs led to considerably lower SBP after 12 months for patients at high cardiovascular risk [51].

Role of Physicians:

By prescribing reasonably priced medications, reducing the frequency of dose and the quantity of tablets, and offering information and encouragement, doctors play a critical role in improving patients' adherence to medication. Research indicates that once-daily dosing and single-pill combinations enhance adherence to medication therapy. Frequent office visits for routine blood pressure checks can also maintain patient involvement and promote ongoing adherence to recommended therapies. In order to increase accessibility and lower treatment costs, doctors are urged to give preference to generic medications over more costly branded ones wherever feasible [52].

Role of Health Authorities:

In developing nations, health authorities play a vital role in guaranteeing the availability of national health insurance, which is frequently lacking in low-income nations. Regulations to lower the amount of salt in processed foods and restaurant offers should be established, essential drug lists should be created, and policies favoring generic drugs should be promoted. Health authorities should also support the establishment of specialized hypertension clinics, encourage opportunistic blood pressure tests, and fund educational initiatives for medical professionals. According to data from a multicomponent intervention in Argentina, individuals with uncontrolled hypertension who took part in programs run by community health workers saw a greater drop in blood pressure than those who received standard care [53]. Health officials must also make reasonably priced blood pressure-lowering drugs more accessible.

Role of Nurses and Pharmacists:

The role of nurses is growing in developing nations where the prevalence of hypertension is increasing. Nurses help with blood pressure monitoring and measurement, patient education, and medication reminders and follow-up consultations. They oversee hypertension services in a variety of contexts, including schools, workplaces, and communities. Blood pressure control rates have been shown to be higher in nurse-led hypertension management programs than in standard care [54]. In sub-Saharan Africa, nurse-led clinics have also shown promise in both rural and urban settings [55], with patients receiving nurse-led care more likely to comply with medication regimens and obtain blood pressure-lowering treatments. In addition to standard care, a nurse-led home-delivered health promotion program in Mexico produced notable drops in blood pressure in the intervention group when compared to control groups [56]. Pharmacists are important in the treatment of hypertension as well. The effect of pharmacist-led treatment on controlling cardiovascular disease risk variables in outpatients was examined by Santschi et al. [57], who discovered that pharmacist care was linked to notable drops in both systolic and diastolic blood pressure. Using a multidisciplinary team approach is one of the best ways to treat hypertension. In comparison to usual care, randomized controlled trials (RCTs) of team-based hypertension therapy, which included nurse or pharmacist interventions, showed improvements in blood pressure control targets and decreased both SBP and diastolic blood pressure (DBP) [58].

Adherence Improving Interventions:

About half of patients who start treatment for hypertension stop taking their antihypertensive drugs [59, 60]. This is a common problem in underdeveloped nations. One important component of increasing adherence in an economical way has been found to be patient education [62]. Furthermore, lowering the daily dose frequency can greatly improve adherence, which makes it a crucial first-line strategy for the treatment of hypertension [63]. Since drug costs usually make up the majority of healthcare expenditures, it is also imperative to ensure inexpensive access to pharmaceuticals. Antihypertensive pharmaceuticals can be made more accessible and affordable in low-resource environments by encouraging local production of

generic products and enforcing price controls [64]. Antihypertensive medicines are now significantly more accessible in underdeveloped nations because to the usage of generic medications [65•]. Medication prices and adherence can be greatly impacted by policies that allow generic substitution, such as requiring pharmacists to provide generic alternatives unless the prescription specifies otherwise. For instance, France saved around US $2 billion in 2008 alone after implementing a national generic substitution policy [66]. Generic drugs can differ in quality, though. 25% of the generic antihypertensive pharmaceuticals on the market were of low quality, according to a research by Terline et al. evaluating five widely used hypertension medications in Sub-Saharan Africa [65•]. Twenty percent of hypertensive medications in Rwanda were subpar, and seventy percent lacked sufficient stability [67]. Governments can reduce the cost of medications and create a foundation for national drug coverage programs by creating and implementing critical medicine lists [68]. To prioritize affordable and life-saving therapies, nations are urged to compile their own lists of critical medications.

Salt Reduction:

Consuming too much salt is a global issue since levels are constantly higher than advised [69]. Reducing salt intake effectively is crucial for lowering the risks of hypertension and cardiovascular disease. To achieve considerable decreases in sodium intake, a more comprehensive public health approach is required, however public education, including clinician counseling, might be helpful. It is advised to have a long-term goal of bringing the world's salt consumption down to 3 grams daily. Public education campaigns, media campaigns, and voluntary food industry initiatives like labeling high-salt packaged foods are among methods for lowering salt intake. It has been shown that national laws restricting the amount of salt added to food are an economical course of action. Reducing dietary salt is recommended by the World Hypertension League and the International Society of Hypertension as a crucial tactic for controlling hypertension [71].

Hypertension Guidelines:

Effective management of hypertension is made more difficult by the lack of national treatment recommendations that are relevant to the circumstances of each nation, especially in developing nations. Things that work well in high-resource situations might not work as well in low-resource ones. Given their limited resources, many developing nations find it difficult to treat everyone whose blood pressure is higher than 140/90 mmHg. As a result, cost-effectiveness must direct treatments, and a crucial element of therapy recommendations is medication affordability. The starting point for antihypertensive treatment might be modified based on the healthcare and economic circumstances of a nation. Depending on a nation's degree of resources, the World Health Organization (WHO) has recommended varying cardiovascular risk thresholds for starting intensive interventions [72]. A paradigm for tailoring hypertension treatment to regional economic and cultural contexts can be found in the guidelines published by the Egyptian Hypertension Society. These guidelines provide a more flexible strategy that takes into consideration the local environment, incorporating evidence-based recommendations while modifying the threshold for treating hypertension based on individual cardiovascular risk [73,74]. Additionally, the WHO advises adopting cardiovascular risk stratification tools, like the WHO/ISH risk prediction charts, which can help guide decision-making in settings with limited resources and need little data [75-86].

Future Requirements:

More Epidemiologic Data:

A significant proportion of countries, particularly in low-resource settings, lack usable data on the prevalence, awareness, treatment, and control of hypertension. This knowledge gap, combined with weak surveillance systems, impedes efforts to manage hypertension effectively. Strengthening country-level surveillance and monitoring should be a priority. Additionally, the influence of socioeconomic factors on hypertension distribution remains unclear, and further research is needed to understand how emerging dietary risk factors, such as sugar and fat intake, and environmental pollution impact hypertension trends. Data on the cost-effectiveness of aggressive hypertension management and strategies to improve detection and adherence to treatment are also essential for informing future public health strategies.

Development of National Programs:

Hypertension control strategies should be tailored to national or regional circumstances, considering cultural, economic, and healthcare differences. National health authorities, in collaboration with the pharmaceutical industry and hypertension societies, should develop and implement comprehensive programs, including:

1. The development and dissemination of hypertension guidelines tailored to the country or region.
2. Public awareness campaigns through various media channels, including social media, press, and television.
3. Salt reduction initiatives, including making healthy, low-salt foods affordable and accessible.
4. Creation of essential medicine lists and promotion of generic drug prescriptions.
5. Establishment of specialized hypertension clinics offering free services for screening, diagnosis, and monitoring.

Routine and opportunistic screening should be encouraged, and blood pressure stations should be established in public spaces such as malls. Successful screening programs must include proper training for

accurate blood pressure measurement, the use of reliable equipment, and clear guidelines for follow-up based on blood pressure readings. Such initiatives can significantly enhance hypertension awareness in developing countries and lead to early intervention.

New Management Tools:

The efficacy and cost-effectiveness of new hypertension management tools must be evaluated in developing countries. Technologies such as electronic health records (EHRs), automated office blood pressure (AOBP) measurement, and telemedicine, particularly home blood pressure tele-monitoring (HBPT), have shown promise in improving hypertension management. While full implementation of electronic health records may be challenging in many countries due to cost, technology limitations, and lack of technical expertise, these systems can substantially enhance the quality of care by ensuring that health information is always accessible. Furthermore, AOBP, which offers greater accuracy and consistency than manual blood pressure measurement, is increasingly recommended in hypertension guidelines and should replace manual methods in routine clinical practice. Telemedicine and HBPT, which involve the transmission of automated blood pressure readings from patients' homes to healthcare providers, have demonstrated benefits in improving blood pressure control. Although the cost of HBPT remains high, its potential to enhance patient outcomes warrants further exploration.

Expanding Financial Coverage for Health Care:

Expanding financial coverage for healthcare, particularly through health insurance or publicly funded programs, should be a priority for governments in low-resource settings. This expansion is vital to improving hypertension control, especially for populations who cannot afford medications or medical care. Studies have shown that health insurance coverage is associated with better hypertension management outcomes in countries like the United States and Taiwan, suggesting that similar approaches could improve hypertension control in developing countries.

Biomarkers for Hypertension:

Hypertension, or high blood pressure, remains one of the leading global health challenges, contributing to an increased risk of cardiovascular diseases, stroke, and kidney failure. Despite the widespread prevalence of hypertension, many individuals remain undiagnosed or poorly managed, partly due to the lack of early biomarkers that can facilitate timely diagnosis and better predict treatment outcomes. Biomarkers in hypertension are increasingly recognized as essential tools for understanding the pathophysiology of the condition, identifying individuals at risk, and personalizing treatment strategies. This paper aims to explore the role of biomarkers in hypertension, focusing on their current applications and potential future directions.

Understanding Hypertension and the Need for Biomarkers

Hypertension is defined as a sustained increase in arterial blood pressure, typically above 140/90 mmHg. It is often asymptomatic, earning it the moniker "silent killer," as it frequently goes undetected until it leads to severe complications. Given the complex nature of hypertension, which can be influenced by genetic, environmental, and lifestyle factors, biomarkers provide an opportunity to identify underlying mechanisms, predict disease progression, and assess the effectiveness of treatments. Unlike conventional diagnostic measures such as blood pressure readings, biomarkers offer the potential for more precise and individualized management of hypertension. Biomarkers can be classified into several categories, including genetic, molecular, and functional biomarkers. They can also serve various purposes in hypertension, ranging from diagnosis and risk stratification to monitoring treatment efficacy and predicting long-term cardiovascular outcomes.

Types of Biomarkers in Hypertension

1. **Genetic Biomarkers**

Genetic predisposition plays a significant role in hypertension, with numerous gene variants identified as contributing to the condition. Family history and the identification of specific genetic polymorphisms can help assess an individual's risk of developing hypertension. For example, mutations in genes related to the renin-angiotensin-aldosterone system (RAAS) or the natriuretic peptide system have been implicated in the pathogenesis of hypertension. Polymorphisms in genes such as the angiotensin-converting enzyme (ACE) gene and the β-adrenergic receptor gene are known to influence blood pressure regulation and may serve as genetic markers for hypertension susceptibility.

Although genetic biomarkers hold promise, their use in clinical practice remains limited due to the complexity of hypertension's polygenic nature and the need for large-scale validation studies. Nonetheless, genetic testing may eventually be integrated into personalized medicine approaches to identify individuals who are genetically predisposed to hypertension and tailor prevention or treatment strategies accordingly.

2. **Molecular Biomarkers**

Molecular biomarkers refer to proteins, peptides, hormones, and other molecules that are indicative of pathological processes in the body. In hypertension, several molecular biomarkers have emerged as valuable indicators of disease progression and treatment response.

- **Plasma Renin Activity (PRA) and Aldosterone**: Both renin and aldosterone are key components of the RAAS, which regulates blood pressure by influencing sodium retention, fluid balance, and vascular tone. Elevated plasma renin activity is

associated with secondary hypertension and may help identify patients who would benefit from renin-angiotensin system blockers, such as ACE inhibitors or angiotensin receptor blockers (ARBs).

- **Natriuretic Peptides**: These peptides, including brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP), are involved in regulating blood volume and vascular tone. Increased levels of BNP are associated with hypertension-induced heart failure and can serve as a prognostic marker for patients with hypertension-related cardiovascular complications.
- **Endothelial Dysfunction Markers**: Endothelial dysfunction, which occurs when the endothelium's ability to regulate vascular tone is impaired, is a hallmark of hypertension. Biomarkers such as asymmetric dimethylarginine (ADMA) and endothelial nitric oxide synthase (eNOS) have been identified as indicators of endothelial dysfunction. These markers can help predict cardiovascular events and assess the effectiveness of antihypertensive treatments that aim to improve endothelial function.

3. **Functional Biomarkers**

Functional biomarkers refer to physiological measures that can be used to assess the functional state of the cardiovascular system. In the context of hypertension, functional biomarkers often include measures of arterial stiffness and vascular reactivity.

- **Pulse Wave Velocity (PWV)**: PWV is a measure of arterial stiffness and is often used as a functional biomarker of vascular health. Increased PWV is associated with chronic hypertension and can predict the risk of cardiovascular events. By measuring the velocity of the pulse wave as it travels through the arteries, PWV offers a non-invasive way to assess vascular function and predict long-term cardiovascular risk.
- **Augmentation Index (AIx)**: The augmentation index measures the extent to which the systolic blood pressure wave is augmented by the reflected wave from the peripheral arteries. AIx is often used to assess the degree of arterial stiffness and may provide insights into the early stages of hypertension-related damage to the vasculature.

Applications of Biomarkers in Hypertension Management

1. **Risk Stratification and Early Diagnosis**

Biomarkers can aid in identifying individuals at high risk of developing hypertension before the onset of clinical symptoms. For instance, measuring molecular biomarkers such as renin and aldosterone levels may help detect individuals with a predisposition to secondary hypertension, enabling early intervention. Moreover, genetic testing may be used to identify individuals with a familial history of hypertension, allowing for proactive blood pressure monitoring and lifestyle modifications.

2. **Treatment Personalization**

Hypertension is a heterogeneous condition, and treatment response can vary significantly among individuals. By using biomarkers to understand the underlying mechanisms of hypertension, clinicians can personalize treatment plans. For example, patients with high renin levels may benefit from RAAS inhibitors, while those with endothelial dysfunction may respond better to therapies that improve vascular health. The use of biomarkers to guide treatment selection could improve the efficacy of antihypertensive therapies and reduce the incidence of adverse events.

3. **Monitoring Treatment Efficacy and Prognosis**

Biomarkers can be used to monitor the efficacy of hypertension treatments. For example, measuring natriuretic peptide levels or endothelial dysfunction markers can help assess whether a patient's blood pressure control is improving or if further adjustments to treatment are necessary. Additionally, biomarkers such as PWV and AIx can help predict long-term outcomes, allowing clinicians to adjust therapies to prevent complications such as heart failure or stroke.

Future Directions and Challenges

The future of biomarkers in hypertension lies in the development of more precise, cost-effective, and accessible tests. Advances in genomics, proteomics, and metabolomics hold the potential to uncover new biomarkers that can be used to detect hypertension earlier, predict treatment responses more accurately, and monitor disease progression more effectively. Additionally, integrating biomarkers with emerging technologies such as telemedicine and electronic health records could revolutionize hypertension management, offering real-time monitoring and personalized care. However, significant challenges remain, including the need for large-scale clinical trials to validate biomarkers' utility, standardize testing methods, and determine the cost-effectiveness of biomarker-driven approaches. Additionally, the integration of biomarkers into routine clinical practice will require collaboration among researchers, clinicians, and policymakers to ensure equitable access to diagnostic tools across diverse populations.



Figure 1: Biomarkers for Hypertension.

Conclusion:

Hypertension is a global epidemic with severe health consequences, particularly given its asymptomatic nature and association with cardiovascular diseases, stroke, and kidney failure. Despite its high prevalence, the control, awareness, and treatment rates remain unsatisfactory, with many individuals undiagnosed or inadequately managed. A multifaceted approach is essential for tackling this public health crisis, encompassing patient education, physician involvement, and active participation from health authorities. Nurses and pharmacists, in particular, play a crucial role in enhancing treatment adherence, implementing interventions, and fostering patient engagement in managing their blood pressure. Emerging risk factors, such as sugar intake, air and noise pollution, low birth weight, complicate hypertension management. These factors contribute to the increasing complexity of understanding and treating hypertension, highlighting the need for a broader perspective on its pathophysiology. Although traditional risk factors such as age, obesity, and family history remain critical, emerging evidence suggests that environmental and dietary factors significantly affect the prevalence and severity of hypertension, particularly in urban and developing areas. Accurate diagnosis remains a significant challenge in hypertension management. Routine screening and early detection are essential, but many healthcare systems, especially in low-resource settings, lack the necessary infrastructure to provide consistent and reliable blood pressure measurements.

The introduction of new management tools, such as electronic health records, automated blood pressure devices, and telemedicine, holds great potential for improving diagnosis and treatment adherence. These tools can enhance the precision of blood pressure measurement, enable remote monitoring, and facilitate timely interventions. Biomarkers play a critical role in improving the management of hypertension. Genetic biomarkers can provide insights into an individual's predisposition to hypertension, allowing for targeted prevention strategies and personalized treatment approaches. Molecular biomarkers, such as renin and aldosterone, are valuable in diagnosing secondary hypertension and monitoring the effectiveness of specific treatments. Functional biomarkers, like pulse wave velocity, offer insights into arterial stiffness and vascular health, predicting long-term outcomes. Integrating these biomarkers into clinical practice will allow for more personalized care, improved risk stratification, and better long-term outcomes. Moreover, public health initiatives aimed at reducing sodium intake and improving patient education are crucial for enhancing hypertension control. Salt reduction campaigns and the promotion of low-sodium diets can have a significant impact on reducing blood pressure across populations. National hypertension programs, tailored to specific cultural and regional needs, can help improve awareness and foster behavior change. These programs should include the development of hypertension guidelines, routine screening initiatives, and collaboration between healthcare professionals to promote better blood pressure management. Financial coverage for hypertension treatment is also essential, particularly in developing countries where access to healthcare and medication is limited. Expanding financial coverage for essential drugs and diagnostic services will ensure that hypertension management is accessible to all segments of society, especially the poor. Governments and health authorities must prioritize hypertension control as part of a broader strategy for managing non-communicable diseases (NCDs). The future of hypertension management requires a comprehensive approach that integrates emerging scientific insights, technological advancements, and personalized healthcare strategies. National programs must be adapted to local contexts and resources, with a focus on improving early diagnosis, enhancing treatment adherence, and leveraging biomarkers for better management. Nurses and healthcare providers should work together to improve patient engagement, encourage lifestyle modifications, and ensure that treatment is accessible, effective, and sustainable. The integration of biomarkers into clinical practice, alongside innovative management tools and patient-centered care strategies, will significantly improve hypertension outcomes. However, challenges such as high costs, limited infrastructure, and the need for ongoing education and

training must be addressed to make these advances widely accessible. Ultimately, the goal is to reduce the burden of hypertension globally, prevent its complications, and improve the overall health and quality of life of individuals affected by the condition. By addressing these issues collectively, there is potential to make significant strides in hypertension control, resulting in better health outcomes worldwide.

References:

1. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants. Lancet. 2011;377(9765):568–77.
2. Agyemang C, Bruijnzeels MA, Owusu-Dabo E. Factors associated with hypertension awareness, treatment, and control in Ghana, West Africa. J Hum Hypertens. 2005;20(1):67–71.
3. Bernabé-Ortiz A, Carrillo-Larco RM, Gilman RH, Checkley W, Smeeth L, Miranda JJ, et al. Impact of urbanisation and altitude on the incidence of, and risk factors for hypertension. Heart. 2017;103(11):827–33.
4. Godfrey R, Julien M. Urbanisation and health. Clin Med (Lond) 2005; 5(2):137–141.
5. Danaei G, Singh GM, Paciorek CJ, Lin JK, Cowan MJ, Finucane MM, et al. The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008. Circulation. 2013;127:1493–502.
6. Zeba AN, Yaméogo MT, Tougouma SJ, Kassié D, Fournet F. Can urbanization, social and spatial disparities help to understand the rise of cardiometabolic risk factors in Bobo-Dioulasso? A study in a secondary city of Burkina Faso, West Africa. Int J Environ Res Public Health. 2017;14(4):378.
7. Mannucci PM, Franchini M. Health effects of ambient air pollution in developing countries. Int J Environ Res Public Health. 2017;14(9):1048–56.
8. Ezejimofor MC, Uthman OA, Maduka O, Ezeabasili AC, Onwuchekwa AC, Ezejimofor BC, et al. The burden of hypertension in an oil- and gas-polluted environment: a comparative cross-sectional study. Am J Hypertens. 2016 Aug;29(8):925–33.
9. Dong GH, Qian ZM, Xaverius PK, Trevathan E, Maalouf S, Parker J, et al. Association between long-term air pollution and increased blood pressure and hypertension in China. Hypertension. 2013 Mar;61(3):578–84.
10. Shrestha A, Shiqi M. Occupational noise exposure in relation to hypertension: a cross-sectional study in the steel factory. Occup Med Health Aff. 2017;5:306–16.
11. de Souza TC, Périssé AR, Moura M. Noise exposure and hypertension: investigation of a silent relationship. BMC Public Health. 2015;15:328.
12. Ediriweera DS, Dilina N, Perera U, Flores F, Samita S. Risk of low birth weight on adulthood hypertension—evidence from a tertiary care hospital in a South Asian country, Sri Lanka: a retrospective cohort study. BMC Public Health. 2017;17(1):358.
13. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441–50.
14. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959–68.
15. Lloyd-Sherlock P, Ebrahim S, Grosskurth H. Is hypertension the new HIV epidemic? Int J Epidemiol. 2014;43(1):8–10.
16. Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N, et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open. 2013;3(8):e003423.
17. Hussain MA, Al Mamun A, Peters SA, Woodward M, Huxley RR. The burden of cardiovascular disease attributable to major modifiable risk factors in Indonesia. J Epidemiol. 2016;26(10):515–21.
18. Wang J, Zhang L, Wang F, Liu L, Wang H, China National Survey of Chronic Kidney Disease Working Group. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens. 2014;27(11):1355–61.
19. Irazola VE, Gutierrez L, Bloomfield GS, Carrillo-Larco RM, Prabhakaran D, Gaziano T, et al. Hypertension prevalence, awareness, treatment, and control in selected communities of nine low- and middle income countries: results from the NHLBI/UHG network of centers of excellence for chronic diseases. Glob Heart. 2016;11(1):47–59.
20. Popkin BM. Global nutrition dynamics: the world is shifting rapidly toward a diet linked with noncommunicable diseases. Am J Clin Nutr. 2006;84:289–98.
21. Siervo M, Montagnese C, Mathers JC, Soroka KR, Stephan BC, Wells JC. Sugar consumption and global prevalence of obesity and hypertension: an ecological analysis. Public Health Nutr. 2014;17(3):587–96.
22. Noubiap JJ, Bigna JJ, Nansseu JR. Low sodium and high potassium intake for cardiovascular prevention: evidence revisited with emphasis on

challenges in sub-Saharan Africa. J Clin Hypertens (Greenwich). 2015;17(1):81–3.
23. Luma GB, Spiotta RT. Hypertension in children and adolescents. Am Fam Physician. 2006;73:1558–68.
24. Önsüz FM, Demir F. Prevalence of hypertension and its association with obesity among school children aged 6-15 living in Sakarya Province in Turkey. Turk J Med Sci. 2015;45(4):907–12.
25. Te Morenga LA, Howatson AJ, Jones RM, Mann J. Dietary sugars and cardiometabolic risk: systematic review and meta-analyses of randomized controlled trials of the effects on blood pressure and lipids. Am J Clin Nutr. 2014;100(1):65–79.
26. Malik AH, Akram Y, Shetty S, Malik SS, Yanchou Njike V. Impact of sugar-sweetened beverages on blood pressure. Am J Cardiol. 2014;113(9):1574–80.
27. Brown IJ, Stamler J, Van Horn L, et al. Sugar-sweetened beverage, sugar intake of individuals and their blood pressure: INTERMAP Study. Hypertension. 2011;57(4):695–701.
28. Johnson RJ, Segal MS, Sautin Y, Nakagawa T, Feig DI, Kang DH, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr. 2007;86(4):899–906.
29. Schmidhuber J, Shetty P. The nutrition transition to 2030. Why developing countries are likely to bear the major burden. Acta Agric Scand Sect C Food Econ. 2005;2(3–4):150–66.
30. Ruxton CH, Gardner EJ, McNulty HM. Is sugar consumption detrimental to health? A review of the evidence 1995–2006. Crit Rev Food Sci Nutr. 2010;50(1):1–19.
31. Johnson RK, Appel LJ, Brands M, Howard BV, Lefevre M, Lustig RH, et al. Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2009;120(11):1011–20.
32. Lee AC, Katz J, Blencowe H, Cousens S, Kozuki N, Vogel JP, et al. National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010. Lancet Glob Health. 2013;1(1):e26–36.
33. WHO Statistics. East Mediterranean Region 2016. http://apps.who.int/iris/bitstream/10665/112738/1/9789240692671_eng.pdf.
34. Law CM, Egger P, Dada O, Delgado H, Kylberg E, Lavin P, et al. Body size at birth and blood pressure among children in developing countries. Int J Epidemiol. 2001;30(1):52–7.
35. World Health Organization Spending on Health. A global overview. Fact Sheet no. 319. April 2012. http://www.who.int/mediacentre/factsheets/fs319/en/.
36. Sliwa K, Stewart S. A low-cost solar-powered blood-pressure device. Lancet. 2011;378(9792):647–8.
37. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B, Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.
38. Gabb GM, Mangoni AA, Anderson CS, Cowley D, Dowden JS, Golledge J, et al. Guideline for the diagnosis and management of hypertension in adults—2016. Med J Aust. 2016;25(2):85–9.
39. Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, et al. Hypertens Canada's 2017 GUIDELINES for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33(5):557–76.
40. Campbell NR, Berbari AE, Cloutier L, Gelfer M, Kenerson JG, Khalsa TK, et al. Policy statement of the world hypertension league on noninvasive blood pressure measurement devices and blood pressure measurement in the clinical or community setting. J Clin Hypertens (Greenwich). 2014;16(5):320–2.
41. World Health Organization. Affordable technology, blood pressure measuring devices for low resource settings. Report 1-26. Geneva: World Health Organization; 2005.
42. Adeloye D, Basquill C. Estimating the prevalence and awareness rates of hypertension in Africa: a systematic analysis. Schnabel RB, ed. PLoS One. 2014;9(8):e104300.
43. Devkota S, Dhungana RR, Pandey AR, Bista B, Panthi S, Thakur KK, et al. Barriers to treatment and control of hypertension among hypertensive participants: a community-based cross-sectional mixed method study in municipalities of Kathmandu, Nepal. Front Cardiovasc Med. 2016;3:26. https://doi.org/10.3389/fcvm.2016.00026.
44. Marshall IJ, Wolfe CD, McKevitt C. Lay perspectives on hypertension and drug adherence: systematic review of qualitative research. BMJ. 2012;344:e3953.
45. Risso-Gill I, Balabanova D, Majid F, Ng KK, Yusoff K, Mustapha F, et al. Understanding the modifiable health systems barriers to hypertension management in Malaysia: a multi-method health systems appraisal approach. BMC Health Serv Res. 2015;15:254.
46. Attaei MW, Khatib R, McKee M, Lear S, Dagenais G, Igumbor EU, et al. Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet Public Health. 2017;2(9):e411–9.
47. Agarwal R, Bills JE, Hecht TJ, Light RP. Role of home blood pressure monitoring in overcoming

therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension. 2011;57(1):29–38.
48. Angell S, Guthartz S, Dalal M, Foster V, Pogue V, Wei A, et al. Integrating self blood pressure monitoring into the routine management of uncontrolled hypertension: translating evidence to practice. J Clin Hypertens. 2013;15:180–5.
49. Anderson C, Dadabhai S, Damasceno A, Dzudie A, Islam SMS, Kamath D, et al. Home blood pressure management intervention in low- to middle-income countries: protocol for a mixed methods study. JMIR Res Protoc. 2017;6(10):e188.
50. Piette JD, Datwani H, Gaudioso S, Foster SM, Westphal J, Perry W, et al. Hypertension management using mobile technology and home blood pressure monitoring: results of a randomized trial in two low/middle-income countries. Telemed J E Health. 2012;18(8):613–20.
51. McManus RJ, Mant J, Haque MS, Bray EP, Bryan S, Greenfield SM, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA. 2014;312(8):799–808.
52. Choudhry NK, Denberg TD, Qaseem A. Improving adherence to therapy and clinical outcomes while containing costs: opportunities from the greater use of generic medications: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2016;164:41–9.
53. HE J, Irazola V, Mills KT, Poggio R, et al. Effect of a community health worker-led multicomponent intervention on blood pressure control in low-income patients in Argentina: a randomized clinical trial. JAMA. 2017;318:1016–25.
54. Himmelfarb CR, Commodore-Mensah Y, Hill MN. Expanding the role of nurses to improve hypertension care and control globally. Ann Glob Health. 2016;82(2):243–53.
55. Kengne AP, Awah PK, Fezeu LL, Sobngwi E, Mbanya JC. Primary health care for hypertension by nurses in rural and urban sub-Saharan Africa. J Clin Hypertens (Greenwich). 2009;11(10):564–72.
56. Garcia-Peña C, Thorogood M, Armstrong B, Reyes-Frausto S, Muñoz O. Pragmatic randomized trial of home visits by a nurse to elderly people with hypertension in Mexico. Int J Epidemiol. 2001;30(6):1485–91.
57. Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med. 2011;171:1441–53.
58. Carter BL, Bosworth HB, Green BB. The hypertension team: the role of the pharmacist, nurse, and teamwork in hypertension therapy. J Clin Hypertens (Greenwich). 2012;14(1):51–65.
59. Nielsen JØ, Shrestha AD, Neupane D, Kallestrup P. Non-adherence to anti-hypertensive medication in low- and middle-income countries: a systematic review and meta-analysis of 92443 subjects. J Hum Hypertens. 2017;31(1):14–21.
60. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62:218–25.
61. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–7.
62. Chapman RH, Kowal SL, Cherry SB, Ferrufino CP, Roberts CS, Chen L. The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications. Value Health. 2010;13:685–94.
63. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev. 2004;2:CD004804.
64. Hogerzeil HV, Liberman J, Wirtz VJ, Kishore SP, Selvaraj S, Kiddell-Monroe R, et al. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. Lancet. 2013;381(9867):680–9.
65. Macquart de Terline D, Diop BI, Bernard M, Do B, Ikama MS, N'guetta R, Balde DM, Tchabi Y, Sidi Aly A, Ali Toure I, Zabsonre P, Damorou JF, Takombe JL, Narayanan K, Fernandez C, Tafflet M, Plouin PF, Empana JP, Marijon E, Jouven X, Antignac M. Substandard drugs among five common antihypertensive generic medications: an analysis from 10 African countries. J Hypertens. 2017;36(2):395–401.
66. WHO. Health systems financing: the path to universal coverage. www.who.int/whr/2010/en/.
67. Twagirumukiza M, Cosijns A, Pringels E, Remon JP, Vervaet C, Van Bortel L. Influence of tropical climate conditions on the quality of antihypertensive drugs from Rwandan pharmacies. Am J Trop Med Hyg. 2009;81(5):776–81.
68. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373(9659):240–9.
69. Newson RS, Lion R, Meijer GW, Neufingerl N, van Zweden R, Feunekes GIJ, et al. Barriers for

progress in salt reduction in the general population. An international study. Appetite. 2013;71(1):22–3.
70. Cobb LK, Appel LJ, Anderson CAM. Strategies to reduce dietary sodium intake. Curr Treat Options Cardiovasc Med. 2012;14(4):425–34.
71. Campbell NR, Lackland DT, Chockalingam A, Lisheng L, Harrap SB, Touyz RM, et al. The International Society of Hypertension and World Hypertension League call on governments, nongovernmental organizations and the food industry to work to reduce dietary sodium. J Hypertens. 2014;32(2):446–7.
72. Modesti PA, Agostoni P, Agyemang C, Basu S, Benetos A, Cappuccio FP, et al. Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings. J Hypertens. 2014;32(5):951–60.
73. Ibrahim MM. The Egyptian hypertension society: Egyptian hypertension guidelines. Egypt Heart J. 2014;66:79–132.
74. López-Jaramillo P, Coca A, Sánchez R, Zanchetti A, Latin American Society of Hypertension. Hypertension guidelines: is it time to reappraise blood pressure thresholds and targets? Position statement of the Latin American Society of Hypertension. Hypertension. 2016;68(2):257–62.
75. Mendis S, Lindholm LH, Mancia G, Whitworth J, Alderman M, Lim S, et al. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens. 2007;25(8):1578–82.
76. Campbell N, Young ER, Drouin D, Legowski B, Adams MA, Farrell J, et al. A framework for discussion on how to improve prevention, management and control of hypertension in Canada. Can J Cardiol. 2012;28:262–9.
77. Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol. 2014;63(12):1230–8.
78. Mangat BK, Campbell N, Mohan S, Niebylski ML, Khalsa TK, Berbari AE, et al. Resources for blood pressure screening programs in low resource settings: a guide from the world hypertension league. J Clin Hypertens (Greenwich). 2015;17:418–20.
79. Maurer J, Ramos A. One-year routine opportunistic screening for hypertension in formal medical settings and potential improvements in hypertension awareness among older persons in developing countries: evidence from the Study on Global Ageing and Adult Health (SAGE). Am J Epidemiol. 2015 Feb 1;181(3):180–4.
80. MG1 M. Replacing manual sphygmomanometers with automated blood pressure measurement in routine clinical practice. Clin Exp Pharmacol Physiol. 2014;41(1):46–53.
81. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.
82. Mboni S, Ferrari R. The role of telemedicine in hypertension management: focus on blood pressure telemonitoring. Curr Hypertens Rep. 2015;17(4):535.
83. Omboni S, Gazzola T, Carabelli G, Parati G. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013;31:455–68.
84. Maimaris W, Paty J, Perel P, Legido-Quigley H, Balabanova D, Nieuwlaat R, et al. The influence of health systems on hypertension awareness, treatment, and control: a systematic literature review. PLoS Med. 2013;10(7):e1001490.
85. Su TC, Bai CH, Chang HY, You SL, Chien KL, Chen MF, et al. Evidence for improved control of hypertension in Taiwan: 1993–2002. J Hypertens. 2008;26(3):600–6.
86. Krishna, A., Murali, S., Moran, A. E., Saxena, A., Gill, S. S., Hering, D., & Kaur, P. (2023). Peer Reviewed: Understanding the Role of Staff Nurses in Hypertension Management in Primary Care Facilities in India: A Time-Motion Study. *Preventing Chronic Disease, 20*.